title: Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin.
abstract: Despite improvements in treatment regimens for osteosarcoma (OS) patients, survival rate has not increased over the last two decades. New treatment modalities are therefore warranted. Preclinical results with conditionally replicative adenoviruses (CRAds) to treat OS are promising. One type of CRAd that was effective against OS cells is Ad5-Delta24RGD. In other types of cancer, CRAds have been shown to interact synergistically with chemotherapeutic agents. Chemotherapy for OS often includes doxorubicin and cisplatin. Therefore, we explored combination treatment of OS cell lines and primary OS cell cultures with Ad5-Delta24RGD and doxorubicin or cisplatin. On OS cell lines, combination treatment was additive to synergistic. Surprisingly, however, on seven of eight primary OS samples no such combination effects were observed. In contrast, in many cases chemotherapy even inhibited CRAd-mediated cell killing. The inhibitory effect of doxorubicin on Ad5-Delta24RGD in primary OS cells appeared to correlate with slow cell growth rate; reduced viral replication and absence of chemotherapy-induced G2 cell cycle arrest. Our results point to the possibility that, at least for OS, virotherapy and chemotherapy should best not be performed simultaneously. In general, our work underscores the importance of testing new genetic anticancer agents and treatment regimens on primary cancer specimens.
authors.affiliation: Department of Orthopedic Surgery, VU University Medical Center, Amsterdam, The Netherlands. gaetan.des-guetz@wanadoo.fr
authors.forename: H C A
authors.initials: HC
authors.lastname: Graat
authors.forename: M A
authors.initials: MA
authors.lastname: Witlox
authors.forename: F H E
authors.initials: FH
authors.lastname: Schagen
authors.forename: G J L
authors.initials: GJ
authors.lastname: Kaspers
authors.forename: M N
authors.initials: MN
authors.lastname: Helder
authors.forename: J
authors.initials: J
authors.lastname: Bras
authors.forename: G R
authors.initials: GR
authors.lastname: Schaap
authors.forename: W R
authors.initials: WR
authors.lastname: Gerritsen
authors.forename: P I J M
authors.initials: PI
authors.lastname: Wuisman
authors.forename: V W
authors.initials: VW
authors.lastname: van Beusechem
mesh_terms: D000256:Adenoviridae / Q000502:physiology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology*; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000494:pharmacology*; D006801:Humans; D050130:Oncolytic Virotherapy; D012516:Osteosarcoma / Q000628:therapy / Q000821:virology*
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin; D002945:Cisplatin